There aren’t many downsides to summer, but one that gets many people in a twist is the incomprehensible heat, and the subsequent sweating that comes with it. While perspiring isn’t limited to hot weather (or board presentations, court dates and annual evaluations with the boss, for that matter), some people also suffer from a serious syndrome of full-body sweating, hyperhidrosis. Currently, people with hyperhidrosis (about 2% to 3% of the population) can be prescribed a pill to combat their perspiration levels, but there are side effects, such as dry eyes, dry skin, dry hair, as well as some cardiac effects that can occur. But help may be on the way.

During a recent chat with Manhattan dermatologist Dr. Gary Goldenberg, he discussed an Alpha-1 adrenergic inhibitor in topical form has been created to target sweat glands, essentially “telling them not to contract and release as much sweat as they do.” The innovation is that the delivery system has been upgraded to a wipe, which is currently under FDA review. Dermira, the Meno Park, Calif-based biopharmaceutical company responsible for the topical sweat inhibitor, could unveil the product as early as July, in line with the dermatology field’s largest event of the year, the 2018 Summer Meeting of the American Academy of Dermatologists.

“In my opinion, I think this is going to be big, especially if it is going to be inexpensive, or if it’s covered by insurance. I see potential for a lot of people in the public domain for this product,” said Dr. Goldenberg. The popularity of the product, which still doesn’t have a brand name, has the potential to trickle down to the masses, of course. And who knows, maybe a beauty firm with a wellness bent will see an opportunity for a product collaboration.